By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intercept Pharmaceuticals 

New York City  New York    U.S.A.
Phone: n/a Fax:



Company News
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/12/2014 6:07:48 AM
Intercept Pharmaceuticals (ICPT) Reports Second Quarter 2014 Financial Results And Provides Business Update 8/11/2014 4:55:21 PM
Intercept Pharmaceuticals (ICPT) Names Lazar Partners Agency Of Record 7/10/2014 10:44:00 AM
Intercept Pharmaceuticals (ICPT) To Present At Upcoming Investor Conferences 6/6/2014 9:34:15 AM
Intercept Pharmaceuticals (ICPT) Announces That FDA Grants Fast Track Designation To Obeticholic Acid For The Treatment Of Patients With Primary Biliary Cirrhosis 5/29/2014 9:09:47 AM
Intercept Pharmaceuticals (ICPT) Reports Additional Positive OCA Data In Patients With Bile Acid Diarrhea At Digestive Disease Week 5/7/2014 9:15:46 AM
Intercept Pharmaceuticals (ICPT) Appoints Rachel Mcminn, Ph.D. As Chief Strategy Officer 4/30/2014 3:53:09 PM
Intercept Pharmaceuticals (ICPT) Reports Additional Positive Data From POISE Trial At EASL Late-Breaker Session 4/14/2014 6:37:05 AM
Intercept Pharmaceuticals (ICPT) Announces Preclinical Data Demonstrating OCA's Potential Role In Preventing Complications Of Cirrhosis 4/11/2014 6:59:17 AM
Data From Intercept Pharmaceuticals (ICPT)'s Pivotal Phase 3 POISE Trial Of Its FXR Agonist Obeticholic Acid To Treat Primary Biliary Cirrhosis And Other Key Obeticholic Acid Data To Be Presented At EASL 2014 4/7/2014 8:53:16 AM